Virco News

Mechelen, Belgium. July 10, 2006 - Virco launches a new version of the virco®TYPE HIV-1 Resistance Analysis, version 4.0., produced with a new bioinformatics engine, Virtual Phenotype- LM. This new Linear Modeling (LM) approach more fully utilizes the power of Virco's correlative database of more than 45,000 matched pairs...

Mechelen, Belgium. April 19, 2006 - Virco Presentation on new Tipranavir Clinical Cut-Offs wins Award for best Commercial presentation at 4th European Resistance Workshop. Dr. Lee Bacheler's presentation "Clinically Relevant Phenotypic Resistance and Cross Resistance to Tipranavir among Recent Routine Clinical Isolates" was selected as the best presentation from...

Mechelen, Belgium. March 27, 2006 - Virco has signed an exclusive contract with the HCIDC for national resistance testing services over a period of three years. The HCIDC or Helenic Center for Infectious Disease Control (http://www.keel.org.gr/en/), is the Greek equivalent of the American CDC in Atlanta and is empowered...

Mechelen, Belgium. March 22, 2006 - Virco has been granted an exclusive tender for vircoTYPE HIV-1 and Antivirogram resistance testing services for the province of Quebec Canada commencing June 2006. Enabled via three local laboratories; INSPQ (Laboratoire de Santé Publique du Quebec - LSPQ, Jewish General Hospital Montréal and...

Mechelen, Belgium. March 10, 2006 - In a recent paper in AIDS 1, Laura Waters and co-workers from Chelsea & Westminster Hospital (London, UK) report the success rate of genotypic resistance testing performed at Virco's laboratories in HIV-1 infected individuals with detectable viraemia between 50 and 1000 copies/ml. In...

Mechelen, Belgium. December 1, 2005 - Virco is pleased to announce the launch of a new technology to generate recombinant viruses for its Phenotyping (Antivirogram) service. This novel new nucleofection technology is especially designed for the needs of primary cells and hard-to-transfect cell lines. It delivers DNA directly into...

Unprecedented decision gives HIV patients wider access to innovative technology. Wednesday, November 23, 2005. The Center for Medicare & Medicaid Services (CMS) announced a Medicare reimbursement rate for CPT code 87900, a new code for 2006 that describes the virco®TYPE HIV-1 analysis. This service is used to help determine...

The following information is aimed at providing assistance in interpreting fold-change (FC) information included in the vircoTYPE HIV-1 Resistance Report. Currently, the vircoTYPE HIV-1 Report provides on its first page a biological cut-off (BCO) of 1.6 for the interpretation of tipranavir-specific FC values. The resistance calls provided on the...

For the occasion of a Pre-Congress Workshop on Resistance Testing at the "Deutscher und Oëstereichischer AIDS Kongress" in Vienna (June 1-4), Lee Bacheler, Vice President Clinical Virology, gave a presentation on "Clinical Cut-Offs for Phenotypic Resistance Information". You can now view this presentation on the Virco web site including...

Virco scientists presented data at the 3rd IAS conference on HIV Pathogenesis and Treatment (Rio de Janeiro, 24 - 27 July 2005) indicating that virco®TYPE HIV-1 and Virologic's PhenoSenseTM assays provide comparable resistance results. This is the first time that a direct comparison between the two assays is presented....